AI Article Synopsis
- EGFR and mTOR are key players in tumor growth, leading to the development of targeted cancer therapies that inhibit their functions.
- Research indicates that both EGFR and mTOR are crucial for a strong innate immune response.
- Combining therapies to block EGFR and mTOR could enhance anti-tumor effects, but may increase the risk of severe infections in patients.
Article Abstract
Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/scisignal.2003734 | DOI Listing |
Publication Analysis
Top Keywords
growth factor
8
factor receptor
8
egfr mtor
8
comment "epidermal
4
"epidermal growth
4
receptor essential
4
essential toll-like
4
toll-like receptor
4
receptor signaling"
4
signaling" epidermal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!